Epidermal growth factor (EGF)-like growth factors control tumor progression as well as evasion from the toxic effects of chemotherapy. Accordingly, antibodies targeting the cognate receptors, such as EGFR/ErbB-1 and the coreceptor HER2/ErbB-2, are widely used to treat cancer patients, but agents that target the EGF-like growth factors are not available. To circumvent the existence of 11 distinct ErbB ligands, we constructed a soluble fusion protein (hereinafter: TRAP-Fc) comprising truncated extracellular domains of EGFR/ErbB-1 and ErbB-4. The recombinant TRAP-Fc retained high-affinity ligand binding to EGF-like growth factors and partially inhibited growth of a variety of cultured tumor cells. Consistently, TRAP-Fc displayed an inhibitory effect in xenograft models of human cancer, as well as synergy with chemotherapy. Additionally, TRAP-Fc inhibited invasive growth of mammary tumor cells and reduced their metastatic seeding in the lungs of animals. Taken together, the activities displayed by TRAP-Fc reinforce critical roles of EGF-like growth factors in tumor progression, and they warrant further tests of TRAP-Fc in preclinical models.
Introduction
The ErbB family of receptors and cognate growth factors, all sharing an epidermal growth factor (EGF) module, have important roles in embryonic development and in tissue remodeling throughout adulthood. The signaling cascade downstream of the ligand-ErbB complex initiates upon dimerization of occupied receptors, auto-phosphorylation and activation of various cellular processes, including proliferation and migration (Yarden and Sliwkowski, 2001) . The family includes four receptors: ErbB-1 (EGFR), which binds to EGF, transforming growth factor a (TGFa), the heparin-binding EGF-like growth factor (HB-EGF), amphiregulin, betacellulin, epiregulin and epigen, ErbB-2 (also called HER2), which has no known ligand, and two neuregulin (NRG) receptors ErbB-3 and ErbB-4. The EGF-like module of 50-60 amino acids is shared by all ErbB ligands, as it confers specific receptor binding (Jorissen et al., 2003) . The growth factors are synthesized as type I transmembrane precursors, which comprise an EGF-like domain. Once processed, the soluble ligand may bind and activate receptors on distant cells, neighboring cells or on the cells of its origin, mechanisms termed as endocrine, paracrine and autocrine, respectively (Sporn and Todaro, 1980) .
Several clinical studies indicate that overexpression of one or more EGF-like ligands correlates with decreased patient survival. For example, in colorectal tumors, enhanced expression of TGFa is associated with over 50-fold increased risk of developing liver metastases, and TGFa levels in liver metastases associate with poor patient outcome (De Jong et al., 1998; Barozzi et al., 2002) . Likewise, increased expression of TGFa in head and neck tumors correlates with decreased patient survival (Grandis et al., 1998) . In bladder cancer, the elevated expression of a number of ligands is linked to decreased patient survival (Thogersen et al., 2001) . Moreover, in vivo studies have shown that overexpression of NRG in mammary tissue accelerates adenocarcinoma development (Krane and Leder, 1996) , and favors metastatic spread of breast cancer cells (Atlas et al., 2003) . Likewise, it has recently been proposed that an autocrine loop involving NRG1 and an activated ErbB-3 drives progression of a subset of ovarian tumors (Sheng et al., 2010) . Importantly, ErbB receptors and their ligands are also involved in resistance to endocrine and cytotoxic therapy, as well as to radiotherapy (Bijman et al., 2009; Freeman et al., 2009) .
The currently approved drugs for the treatment of tumors driven by the ErbB family are either monoclonal antibodies (mAbs) directed at ErbB-1/EGFR (for example, cetuximab) or at ErbB-2/HER2 (such as trastuzumab), or small-molecule tyrosine kinase inhibitors (for example, erlotinib) (Britten, 2004; Baselga, 2006; Weiner and Borghaei, 2006) . Although these agents can induce therapeutic responses in specific subsets of patients, acquired resistance to these drugs inevitably emerges. Mechanistically, upregulation of ErbB receptors (Bianchi et al., 2006; Engelman et al., 2007; Karamouzis et al., 2007; Ritter et al., 2007) and EGF family ligands have been proposed as mediators of acquired resistance (Ishikawa et al., 2005; Valabrega et al., 2005; Zhou et al., 2006; Wheeler et al., 2008) . In the same vein, human breast cancer cells selected in vivo for resistance to trastuzumab remarkably overexpress EGFR and specific ErbB ligands (Ritter et al., 2007) . Likewise, EGFR-and ErbB-2-targeting mAbs increase the antitumor effects of docetaxel by blocking functional receptors and drug evasion mechanisms (Bijman et al., 2009; Freeman et al., 2009) .
Taken together, the aforementioned lines of evidence predict that drugs directly intercepting EGF-like growth factors would likely improve response to chemotherapy and to molecular targeted therapies. We recently described a 'tailored' approach that determines which autocrine loops are operating in a specific tumor, and then combines mAbs specific to the respective growth factors (Lindzen et al., 2010) . Because of the multiplicity of EGF-like ligands and the autocrine/ paracrine variation displayed by human tumors, we describe herein an alternative strategy that makes use of a tripartite soluble receptor, denoted TRAP-Fc, comprising portions of the extracellular domains of ErbB-1/ EGFR and ErbB-4.
Results

Construction and expression of TRAP-His fusion proteins
Our working hypothesis assumes that by combining the ligand-binding specificities of ErbB-1/EGFR and either ErbB-3 or ErbB-4, one would generate proteins able to sequester the majority or all EGF-like ligands, respectively, thereby intercept essential autocrine/paracrine loops. As an initial step, we designed four molecular configurations by variably combining the ligand-binding domains of ErbB-1/EGFR, namely domains I, II, III and a part of domain IV, with the respective domains of ErbB-3 or ErbB-4 (Supplementary Figure S1A ). The resulting construct was fused to a six-histidine tag and stably expressed in HEK-293 human kidney cells. Immunoblot analyses detected three of the four fusion proteins in the medium of transfected cells (Supplementary Figure S1B ), and similar analysis of cell lysates confirmed that the TRAP-His not detected in the medium, namely TRAP-His 1-4, was expressed but remained confined to the cytoplasm. Covalent crosslinking of radioactive EGF or NRG1-beta to the TRAP-His molecules validated retention of ligandbinding specificities. As expected, all TRAP-His molecules, as well as IgB-1, a molecule comprising the full-length extracellular domain of ErbB-1/EGFR fused to the Fc portion of human immunoglobulin (Chen et al., 1996) , could bind to EGF, and unlabeled EGF prevented this binding (Supplementary Figure S1C) . Likewise, TRAP-His proteins 1-3 and 3-1 underwent specific cross-linking to NRG1. Binding of EGF to the TRAP-His molecules was further supported by another experiment that assayed cellular uptake of the radioactive ligand (Supplementary Figure S1D) ; HeLa cells were incubated with 125 I-EGF, washed, lysed and the amount of ligand that underwent uptake by the cells was determined. The results we obtained clearly indicated that all secreted TRAP-His molecules decreased uptake of 125 I-EGF, in line with an ability to sequester ligands.
Construction, expression and functional tests of a TRAP-Fc protein
To enhance immunologic compatibility, we replaced the His tag with the Fc domain of human immunoglobulin G. In addition, as ErbB-4 binds to more ligands than ErbB-3 and with higher affinity (Riese and Stern, 1998), we used the successfully secreted ErbB-4-ErbB-1 configuration in subsequent studies. The resulting structure combined a signal peptide, flanked by domains I-III, with a portion of domain IV of ErbB-4, followed by a (Gly 4 Ser) 3 linker domain, and the corresponding part of EGFR ( Figure 1a ). First, we verified secretion of TRAP-Fc from transfected HEK-293 human kidney cells. Under reducing conditions, a single immunoreactive species was detectable in the medium (Figure 1b ). In contrast, under nonreducing conditions, a larger, major immunoreactive species was detected, confirming that the secreted TRAP-Fc represents a disulfide linked dimer molecule.
Using TGFa, HB-EGF and NRG1 along with the three IgB molecules that can bind ligands (namely IgB-1, IgB-3 and IgB-4), we confirmed that the IgBs can bind to the cognate ligands with affinities similar to those of the intact receptors (Chen et al., 1996) , but TRAP-Fc was able to bind all three ligands with apparent affinities similar to or better than the respective IgB molecules (Figure 1c ). Direct determination of binding affinities by surface plasmon resonance demonstrated high-affinity interactions of the TRAP-Fc with ligands that bind EGFR/ErbB-1 and ErbB-3/4 ( Figure 1d ). Notably, the affinities that we observed were in agreement with previous reports (Fitzpatrick et al., 1998; Jones et al., 1999; Domagala et al., 2000) . Next, we examined the ability of TRAP-Fc to inhibit ligand-induced receptor phosphorylation using either HeLa cells (and TGFa) or T47D mammary cells (and NRG1). As shown in Figures 1e and f, increasing concentrations of TRAP-Fc gradually reduced ligand-induced phosphorylation levels. This observation was extended to additional EGF-like ligands from human and rodent origins (Supplementary Figure S2 ). Altogether, the results that we obtained confirmed the ability of TRAP-Fc to effectively sequester multiple growth factors with efficiencies and specificities similar to those displayed by the full-length ectodomains of ErbB-1/EGFR and ErbB-4.
The TRAP-Fc inhibits proliferation of cancer cell lines of different tissue origins Owing to its presumed ability to sequester all known ErbB ligands, we reasoned that TRAP-Fc would reduce the growth of human cancer cell lines of epithelial origin, which often maintain ErbB-mediated autocrine loops (Witsch et al., 2010) . Indeed, dose-dependent inhibition of proliferation, up to 40%, was observed when BxPC3 human pancreatic cells were incubated with increasing concentrations of TRAP-Fc (Figure 2a ). Similar or smaller inhibitory effects were observed with six additional cancer cell lines of mammary, prostate, lung and pancreatic origins ( Figure 2b ), but no statistically consistent inhibition of the PC3 prostate cell line was observed. Likewise, TRAP-Fc inhibited proliferation of lung (H1437), pancreatic (BxPC3) and PC3 cells, which were exposed to exogenously added ligands (that is, NRG1, HB-EGF, TGFa and EGF; Figure 2c ). Similarly, anchorage-independent growth of H1437 lung cancer cells was dramatically decreased in the presence of TRAP-Fc (Figures 2d and e ). In conclusion, the recombinant TRAP-Fc molecule that we constructed can partially inhibit growth of several carcinoma cells under both autocrine and paracrine settings.
Antitumorigenic activities of TRAP-Fc in animal models
The ability of TRAP-Fc to inhibit growth of a wide spectrum of cultured carcinoma cells predicted an antitumorigenic activity in animals. This was assessed using human pancreatic (BxPC3), lung (H1437) and prostate (PC3) xenograft models. Treatment with TRAP-Fc (100 mg/mouse, twice per week) was started only after subcutaneous lesions became palpable. Partial inhibition of all the three xenograft models was induced by the decoy receptor ( Figure 3 ). Moreover, two of the eight BxPC3-treated mice and two of the ten treated PC3 mice completely lost their tumors, but these cases of total regression were excluded from the statistical analyses. It is notable that no significant weight loss was observed in these experiments. For reference, we compared the inhibitory activity of TRAP-Fc with that of a combination of mAbs to TGFa and HB-EGF, growth factors frequently expressed by pancreatic and other tumors. As we previously reported (Lindzen et al., 2010) , treatment with the combination of antibodies partially inhibited tumorigenic growth of BxPC3 and H1437 cells, and in the latter model the inhibitory effect of the decoy was even greater. In conclusion, the TRAP-Fc protein is endowed with an anti-tumorigenic activity towards several different human xenograft models.
TRAP-Fc can sensitize pancreatic tumor cells to both molecular targeted drugs and chemotherapeutic agents
Self-produced growth factors may have essential roles in acquired resistance to chemo-and targeted therapies (Bianchi et al., 2006; Engelman et al., 2007; Karamouzis et al., 2007; Ritter et al., 2007) . Hence, blocking such autocrine loops may resensitize tumors to specific drugs.
As an initial test of this scenario, we examined in vitro the combined effect on pancreatic tumor cells of TRAP-Fc and each of the following agents: mAbs specific to EGFR or to HER2, ErbB-specific tyrosine kinase inhibitors and gemcitabine. The results presented in Figure 4a verified the ability of the TRAP-Fc molecule to augment the inhibitory effects of the EGFR-and HER2-targeting mAbs, namely, cetuximab and trastuzumab, respectively. Combining TRAP-Fc with the tyrosine kinase inhibitors lapatinib, CI-1033 and gefitinib also resulted in statistically significant additive effects. Notably, the largest effect was observed when we combined TRAP-Fc with gemcitabine, the mainstay single-agent drug of advanced pancreatic tumors (Mackenzie 
The TRAP-Fc inhibits proliferation of human tumor cells. (a) BxPC3 pancreatic tumor cells (2 Â 10 4 ) were incubated with increasing concentrations of TRAP-Fc. Cell proliferation was determined in hexaplicates after 5 days, using the MTT assay. Average±s.d. (bars) are indicated. (b) The indicated cancer cells (2 Â 10 4 ) were incubated for 5 days with TRAP-Fc (20 mg/ml) and cell proliferation was determined as in a. (c) H1437 lung tumor cells, PC3 prostate tumor cells and BxPC3 pancreatic tumor cells (each at 2 Â 10 4 cells/well) were incubated with the indicated ligands (5 ng/ml), along with TRAP-Fc (20 mg/ml), and cell proliferation assayed as in a. (d, e) H1437 cells were seeded in agarose (top layer: 0.3% agar; bottom layer: 0.6% agar) in six-well plates (1 Â 10 4 cells/well) and overlaid with medium. TRAP-Fc was added to both the soft agar and to the medium (at 100 mg/ml). Photographs were captured and colony numbers were determined in five randomly chosen high-powered fields. The data represent mean±s.d. The data sets were analyzed for statistically significant differences by using the two-tailed Student's t-test.
and McCollum, 2009 ). Hence, we addressed the effect of the combined treatment in an animal model of pancreatic cancer. BxPC3 cells were injected subcutaneously and allowed to grow until palpable tumors appeared. Thereafter, mice were randomized into four groups, which received no treatment, TRAP-Fc alone (administered for the first 3 weeks only), gemcitabine alone or the combination. Kaplan-Meier analysis of animal survival showed that the combined treatment led to a statistically significant prolongation of survival: the median (95% CI) survival of the control group was 52 ± 1.5 days (blue line; Figure 4b ). Treatment with TRAP-Fc (black line) or gemcitabine alone (green line) moderately prolonged survival to 61 days (P ¼ 0.071) and 64 (P ¼ 0.103) days, respectively, and the combination resulted in the longest prolongation of median survival to 80 days (P ¼ 0.006) (red line). In conclusion, the TRAP-Fc molecule exhibits antitumor activity when tested in animals, and this activity can be enhanced when combined with an established chemotherapeutic agent.
TRAP-Fc inhibits invasive growth of mammary tumor cells
ErbB signaling has been implicated in invasion and metastasis of cancer cells (De Luca et al., 2008) . To test the effect of TRAP-Fc on the ability of cancer cells to invade through tissue barriers, we used the highly metastatic MDA-MB-231 human breast cancer cell line. When plated in a natural preparation of extracellular matrix (Matrigel), MDA-MB-231 cells tend to invade into the surrounding matrix by growing long and branched extensions (Figure 5a , left panel). However, when the TRAP-Fc was added to their medium, the cells exhibited a round, noninvasive morphology (Figure 5a , right panel). We further confirmed the inhibitory effect of TRAP-Fc on cell migration using a dual chamber Transwell tray. Cells were allowed to migrate through pores within a nitrocellulose filter, which separates the chambers. Thereafter, cells that migrated and adhered to the bottom of the filter were photographed, and the percentage of the area that they covered was quantified (Figure 5b) . The results that we obtained in two different experiments indicated that migration of TRAP-Fc-treated cells was inhibited by 27±7%. The 'wound closure' (scratch) assay was used to further test the ability of TRAP-Fc to inhibit collective cell migration of MDA-MB-231 cells. The cells were plated into two compartments separated by an insert, resulting within 24 h in a confluent, but split monolayer. Thereafter, the inserts were removed, TRAP-Fc was added and cells were allowed to migrate. Snapshots taken after 6 h are presented in Figure 5c . By this time, the residual wound areas differed significantly: control cells covered approximately 71.21 ± 0.93% of the gap area, while TRAP-Fctreated cells covered 44.73 ± 2.60% (Figure 5c ), in line with an ability of TRAP-Fc to inhibit collective cell migration.
TRAP-Fc exhibits anti-metastasis activities in an animal model
To examine the effect of the TRAP-Fc on metastasis, we employed MDA-MB-231 cells, which were initially tested in vitro using a cell proliferation assay. As expected, when incubated with TRAP-Fc, the cells exhibited a partial growth-inhibitory effect (Figure 6a ). Hence, we transfected a TRAP-Fc-encoding plasmid into the MDA-MB-231 cells and confirmed expression of the decoy by immunoblotting (Figure 6b ). In the next step, these cells were implanted subcutaneously in the flanks of mice, and both TRAP-Fc concentrations and tumor size were monitored. As expected, persistently high concentrations of TRAP-Fc in tumor correlated with effective growth inhibition (Figure 6c ), which led us to examine the ability of the ectopically expressed decoy to modulate metastasis to the lungs. Parental and TRAP-Fc-expressing MDA-MB-231 cells were injected into the tail vein of severe combined immunodeficiency mice, and two months later lung metastases were assessed by counting the number of nodules. Compared with the parental cells, the TRAP-Fc-secreting MDA-MB-231 cell derivatives displayed an 80% reduction in lung metastasis (Figure 6d ). This antimetastasis effect was verified by using a recombinant TRAP-Fc and the parental MDA-MB-231 cells. Cells were injected into the tail vein of severe combined immunodeficiency mice, and half of the mice were additionally injected intraperitoneally with the TRAP-Fc protein (100 mg/injection) on days 0, 3, 6 and 9. Two months later, we assessed metastasis by counting nodules in the lung. Consistent with the results obtained from the stably expressing clones of MDA-MB-231 cells, the injected TRAP-Fc reduced metastasis to the lung by 46% (Figure 6e ).
In summary, by using human pancreatic, lung, prostate and breast xenografts, we obtained evidence supporting the notion that sequestering multiple EGFlike ligands may bear therapeutic significance in vivo. The therapy that we propose might be especially useful in terms of sensitizing tumors to cytotoxic regimens and delaying onset of chemoresistance. Our results also demonstrate an anti-metastatic activity of the TRAP-Fc molecule in animals, an observation that might be important in clinical settings.
Discussion
Early studies indicated that ligand-blocking anti-receptor antibodies can sensitize tumors to chemotherapy (Aboud-Pirak et al., 1988), a finding that was later translated to combination therapies of colorectal cancer patients, and 19, 28, 32, 35, 39, 42, and 45 . Gemcitabine injections were given on the same days and repeated three more times on days: 49, 52 and 55. Body weights were measured once a week, but no consistent differences were observed (data not shown).
head and neck cancer patients (Baselga, 2006) . These considerations have led to the prediction that sequestration of growth factors would bear therapeutic benefits. Several preclinical attempts to construct and employ decoy receptors have been reported. A truncated ErbB-1/ EGFR sequence fused to a human immunoglobulin domain, designated sEGFR501.Fc, exhibited high affinity for a number of EGFR ligands, but administration of sEGFR501.Fc to mice bearing human xenografts resulted in weak retardation of tumor growth (Adams et al., 2009) . Similarly, moderate to high tumor-inhibitory effects have been reported by a study that separately fused Fc to the full-length extracellular domains of ErbB-1/EGFR and ErbB-3 (Sarup et al., 2008) . It is notable that this strategy results in a mixture of ErbB-1 homodimers, ErbB-3 homodimers and the respective heterodimers, denoted as (HER-1:HER-3)Fc. The TRAP-Fc protein that we constructed combines into a single molecular entity the binding properties of both ErbB-1 and ErbB-4. It is notable that the spectrum of EGF-like ligands that bind to ErbB-4 is wider than that of ErbB-3, and, in addition, ErbB-4 binds to NRGs with higher affinity (Riese and Stern, 1998). Hence, our TRAP-Fc is expected to exhaustively deplete all soluble growth factors of the EGF family. Notably, like sEGFR501.Fc and (HER-1:HER-3)Fc, TRAP-Fc makes use of an Fc domain. In addition, the TRAP-Fc molecule, similarly to (HER-1:HER-3)Fc, makes use of two rather than one receptor, but unlike the fulllength receptors that comprise (HER-1:HER-3)Fc, truncated forms have been used to construct both TRAP-Fc and sEGFR501.Fc. The crystal structures of the ectodomains of both ErbB-1 and ErbB-4 suggest an inhibitory contribution of the distal extracellular subdomain IV, as directly shown for ErbB-1/EGFR (Elleman et al., 2001) . For these and other reasons, TRAP-Fc may open new pharmacological opportunities in terms of the challenges imposed by ligand multiplicity, tumor-specific distinct repertoires of ligands and the roles exerted by EGF family growth factors in frequent emergence of resistance to chemotherapy.
Potentially, anti-ligand antibodies would deplete specific growth factors, similarly to TRAP-Fc. Although no antibody to an EGF-like molecule has so far been approved for clinical applications, it is notable that an HB-EGF inhibitor (CRM197) is active both as a single agent and in combination with other anticancer agents (Sanui et al., 2010; Tsujioka et al., 2011) , and bevacizumab, a therapeutic antibody used to treat colorectal and other tumors, can intercept the vascular endothelial growth factor. In contrast to the vascular endothelial growth factor family, the greater multiplicity of the EGF-family ligands calls for a more general approach, such as the 'tailor made' strategy that we developed (Lindzen et al., 2010) . This strategy employs combinations of mAbs to two or more growth factors, which are secreted by specific tumors. Side-by-side comparison of this approach with TRAP-Fc suggests comparable, if not superior, efficacy of TRAP-Fc (Figure 3 ). However, unlike the 'tailoring' of distinct antibody combinations to specific tumors, application of the TRAP-Fc requires no predetermination of the identity of secreted growth factors. In addition, this strategy may better target tumors whose spectrum of secreted ligands undergoes dynamic changes in response to the metastatic niche, or under cellular stress conditions imposed by irradiation or chemotherapy.
The binding constants of TRAP-Fc are comparable to those displayed by the full-length receptors (Fitzpatrick et al., 1998; Jones et al., 1999; Domagala et al., 2000) . This may explain the in vitro growth-inhibitory activity of TRAP-Fc towards breast, lung, prostate and pancreatic tumor cells, as well as the antitumor activities that we observed using three xenograft models of pancreas, lung and prostate cancer (Figure 3 ). Along the same vein, wide-spectrum ligand sequestration explains the ability of TRAP-Fc to inhibit invasive growth of tumor cells both in vitro and in animals ( Figures 5 and 6) . EGF family growth factors are considered major mediators of epithelial cell invasion across tissue barriers. For example, a comparison between primary lung tumors and the corresponding brain metastases showed significantly higher expression of EGF, amphiregulin, phosphorylated EGFR and phosphorylated ErbB-3 in the metastases (Sun et al., 2009) . Likewise, constitutive activation of ErbB-3 by an autocrine NRG1 contributes to intrahepatic metastasis and to early recurrence of hepatocellular carcinoma (Hsieh et al., 2011) . Our study made use of the highly metastatic MDA-MB-231 breast cancer cell line and found that TRAP-Fc inhibited migration and invasive growth, which translated to a significant reduction in lung metastasis in treated animals.
The ability of the TRAP-Fc to collaborate with currently approved cancer drugs (Figure 4 ) is yet another indication that the decoy molecule would retard late stage tumors and reverse resistance to chemotherapy, as well as to molecular targeted therapies. The latter (for example, kinase inhibitors and anti-receptor antibodies) often elicit resistance due to upregulation of either alternative ErbB family members (Bianchi et al., 2006; Engelman et al., 2007; Karamouzis et al., 2007; Ritter et al., 2007) or certain EGF-family ligands (Ishikawa et al., 2005; Valabrega et al., 2005; Zhou et al., 2006; Wheeler et al., 2008) . Hence, depletion of soluble growth factors in the vicinity of heavily treated tumors and metastases may block escape pathways and delay resistance onset. Although TRAP-Fc comprises of only human-derived amino acid sequences, and the animals we treated showed no remarkable adverse effects, more rigorous toxicological studies are mandatory for examination of the true therapeutic potential of TRAP-Fc in clinical settings.
Materials and methods
Reagents, cells and plasmids
Growth factors were from PeproTech Asia (Rocky Hill, NJ, USA). ATBS (2, 2 0 -Azino-bis (3-ethylbenzthiozoline-6-sulfonic acid) and MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) were purchased from Sigma (St Louis, MO, USA) and Matrigel from BD Biosciences (San Jose, CA, USA). Trastuzumab was purchased from Roche Diagnostics GmbH (Mannheim, Germany), Cetuximab from Merck Serono (Darmstadt, Germany) and Gemcitabine from Eli Lilly (Hampshire, UK). Antibodies to specific phosphotyrosines were purchased from Cell Signaling Technology (Danvers, MA, USA). Horseradish peroxidase-conjugated anti-mouse antibody was purchased from Jackson ImmunoResearch Laboratories (West Grove, PA, USA). Human cancer cell lines were purchased from the American Type Culture Collection (Manassas, VA, USA) and cultured in DME (HeLa, T47D, HEK-293, Panc-1, MiaPaCa and PC3 cells) or RPMI medium (BxPC3, MDA-MB-231, DU145 and H1437) supplemented with 10% fetal calf serum. CD293 serum-free medium was purchased from GIBCO (Invitrogen, Carlsbad, CA, USA). DNA sequences encoding the different TRAP molecules were custom synthesized (Invitrogen) and cloned into pIRES or pcDNA3 plasmids.
Expression and purification of soluble proteins HEK-293 and MDA-MB-231 cells were transfected with expression plasmids using Lipofectamine 2000 (Invitrogen). Conditioned media from drug-selected TRAP-His expressing clones were centrifuged, filtered and imidazole (5 mM) added just before application to a NiNTA column. The column was extensively washed (20 mM Hepes, pH 7.5, 1 M NaCl, 1% Tween 20) and bound proteins eluted with 0.5 M imidazole in saline. Conditioned media from IgB and TRAP-Fc-expressing cells were similarly applied to a column packed with Protein A beads (2 ml). The column was washed and adsorbed proteins eluted with 0.1 M glycine solution (pH 2.7). TRAP-Fc-expressing cells were grown in serum-free CD293 medium at 32 1C.
Cross-linking with BS 3
Recombinant molecules were incubated with 125 I-EGF or 125 I-NRG1 (each at 1.5 ng/ml) in the presence or absence of unlabeled EGF or NRG1 (each at 3.3 mg/ml) and 2 mM BS 3 (Pierce, Rockford, IL, USA). The cross-linking reaction was stopped after a 60-min long incubation at 4 1C by adding glycine (50 mM).
Surface plasmon resonance
Surface plasmon resonance was performed on a Biacore 3000 instrument (Biacore, Uppsala, Sweden). Proteins were diluted in 100 mM sodium acetate (pH 4.6) to 50 mg/ml and immobilized on a CM5 sensor chip. The protein solution was then run over the chip for 5 min at a rate of 10 ml/min. The binding assay was performed by injecting the analyte solutions at 12 different concentrations (1-100 nM) at a flow rate of 20 ml/min at 25 1C. These conditions resulted in a linear relation between protein concentration and maximal (steady-state) response, indicating a pseudo first-order regime in relation to the immobilized ligand. The net signal was obtained by subtracting the blank signal (dextran matrix). The association phase for analyte binding to all ligands was followed for 4 min, and dissociation phases were monitored for 3 min. The response was monitored as a function of time (sensorgram) at 25 1C. Multi-concentration data were fit using BIAevaluation 3.2 software, supplied by Biacore.
Ligand binding assays
Ninety-six-well plates were coated with solutions of the recombinant proteins (8 mg/ml) by incubating overnight at room temperature. Plates were washed, blocked for 1 h with saline containing 1% albumin and 0.05% Tween-20, followed by a 2-h incubation with increasing concentrations of the indicated ligands. After washing, the plates were incubated for 2 h with avidin-bound antibody that targeted a ligand epitope, followed by a 20-min incubation with biotin-horseradish peroxidase. Subsequently, the plates were incubated with ATBS (Sigma). Signals were determined using an enzymelinked immunosorbent assay reader (420 nm).
Cell proliferation and anchorage-independent growth assays Cells were plated in hexaplicate in 96-well plates (2000 cells/ well). Cell proliferation was assayed after 24, 48 or 72 h using the MTT method. To assay anchorage-independent growth, H1437 lung cancer cells were seeded in six-well plates (1 Â 10 4 cells/well), within a top layer of 0.3% agar and a bottom layer of 0.6% agar. TRAP-Fc (100 mg/ml) was added at the beginning of the incubation. During the 14 days of incubation, the dishes were checked every day and media replenished. The assay was repeated twice in triplicates.
Determination of antitumor activities in animals
Female athymic NCr-nude mice (six-week-old) were inoculated subcutaneously with 2 Â 10 6 human cancer cells. Alternatively, MDA-MB-231 cells (2.5 Â 10 6 ) and their derivatives were inoculated into the mammary fat pad of CD-1-NU mice (10-week-old). Once tumors became palpable (5-7 days), the mice were randomized into groups and injected intraperitoneally at the indicated time points with the recombinant proteins, chemotherapy or various combinations. Tumor volumes were monitored twice a week and body weights were measured once a week. When indicated, tumors were removed, homogenized in SBN buffer (1 mM EDTA, pH 7.5, 50 mM Tris-HCl, 150 mM NaCl, 10% Glycerol and 1% NP-40) and electrophoresed.
Morphogenesis assay in 3D culture
Trypsin-treated cells were resuspended in DME/F12 medium supplemented with 4% horse serum, insulin, cholera toxin and hydrocortisone. Eight-chambered plates (BD Biosciences) were coated with 50 ml Matrigel solution/well (Growth Factor Reduced Matrigel from BD Biosciences). MDA-MB-231 cells (2000/well) were mixed 1:1 with medium (4% serum) containing 25% Matrigel and added to chambers.
Cell migration assays MDA-MB231 cells (1.5 Â 10 5 cells/well) were plated in the upper compartment of a 24-well Transwell tray (Corning, Acton, MA, USA). Cells were allowed to migrate through the intervening nitrocellulose membrane (8 mm pore size) during 19 h of incubation at 37 1C. The filter was removed, fixed for 15 min in saline containing paraformaldehyde (3%), and cells were permeabilized in Triton-X-100 (0.05% in saline) and stained with methyl violet. Cells growing on the upper side of the filter were scraped using cotton swabs, whereas cells growing on the bottom side of the membrane were photographed and counted.
Wound closure assays Wound closure assays were performed using iBidi chambers, according to the manufacturer's protocol (iBidi GmbH, Mu¨nchen, Germany). Briefly, MDA-MB-231 cells were trypsinized, resuspended and plated into each well (6.0 Â 10 5 cells/well), resulting in a confluent layer within 24 h. Thereafter, the culture insert from iBidi was removed and cells were allowed to migrate for 6 h.
Determination of anti-metastasis activities MDA-MB-231 cells (1.5 Â 10 5 ) were injected into the tail vein of female severe combined immunodeficiency c.b-17/ICR mice (six-week-old). TRAP-Fc injections were given twice a week in the first 2 weeks. Sixty days later, the mice were killed, their lungs were removed and nodules were counted.
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